SAN DIEGO, Nov. 10 Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced today that Dr. Douglas Taylor has joined the Science Advisory Board of Exosome Sciences, Inc. (ESI). Dr. Taylor is credited with the discovery of tumor-secreted exosomes and is a leading published author on the topic. ESI, a wholly owned subsidiary of Aethlon Medical, was recently formed to leverage the discovery that the HemopurifierŪ, a medical device being advanced as an adjunct therapy for Hepatitis-C (HCV) and other viral pathogens, is capable of capturing exosomes secreted by solid tumors, lymphomas, and leukemia to suppress the immune response in cancer patients. The targeted removal of circulating exosomes to inhibit cancer related immune suppression could increase patient responsiveness to both immunotherapy and chemotherapy.
"We are honored to have Dr. Taylor become the first member of our ESI science advisory board," stated Aethlon Chairman and Chief Executive Officer, Jim Joyce. "As we assemble of team of thought leaders in the emerging exosome field, Dr. Taylor will provide important guidance specific to the treatment and diagnoses of ovarian cancer," concluded Joyce.
About Dr. Douglas Taylor
Dr. Douglas Taylor is currently Professor and Vice Chair for Research in the Department of Obstetrics, Gynecology, and Women's Health at the University of Louisville School of Medicine. He joined the University of Louisville School of Medicine faculty with a joint appointment in the Departments of Obstetrics and Gynecology and Immunology in April 1992. He received his BS for the University of Richmond with a double major in Chemistry and Biology. He earned his Ph.D. for the Bowman Gray School of Medicine of Wake Forest University in 1982. His previous employment experience was as postdoctoral fellow in Immunology at Boston University School of Medicine. In 1988, he joined became Director of Research in the Department of Surgical Oncology at the Fox Chase Cancer Center in Philadelphia. Due to his association with clinical departments, he has extensive experience in development of diagnostic clinical assay systems. In 1979, Dr. Taylor discovered the phenomenon of exosomal shedding and has developed his research project around exosome-based diagnostic markers. He currently has 3 patents submitted on exosome-based diagnostics for cancer and has additional disclosures on technologies associated with the diagnosis of adverse pregnancy outcomes. He has authored over 80 peer-viewed publications and currently has funding from the NIH, the Department of Defense Ovarian Cancer Program, and the March of Dimes.
About Aethlon Medical
Aethlon Medical creates diagnostic and therapeutic device solutions for infectious disease and cancer. Our HemopurifierŪ represents the first-in-class medical device to selectively adsorb viruses and immunosuppressive toxins from the bloodstream. The HemopurifierŪ seeks to improve Hepatitis-C treatment outcomes and serves as a broad-spectrum treatment countermeasure against bioterror and pandemic threats. Additional information regarding Aethlon Medical can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the HemopurifierŪ to reduce viral loads and other disease conditions or to identify disease conditions such as cancer, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts: RedChip Companies, Inc. Jon Cunningham 1-800-733-2447, Ext. 107 [email protected]
Jim Joyce Chairman, CEO 858.459.7800 x301 [email protected]
Jim Frakes Senior VP Finance 858.459.7800 x300 [email protected]
SOURCE Aethlon Medical, Inc.